Kerr on Oncology

David J. Kerr, MD, is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.

+ Add to Email Alerts

FOxTROT Trial Sheds Light on Neoadjuvant Therapy for CRC David J. Kerr, CBE, MD, DSc, discusses lessons learned from the FOxTROT trial, and future directions.
Medscape Oncology, March 16, 2023
Does Somatic Variation Affect ctDNA Testing? David J. Kerr, CBE, MD, DSc, discusses somatic mutations in normal tissue.
Medscape Oncology, March 15, 2023
The End of England's Long-Term National Cancer Plan: Costing Lives? David J. Kerr, CBE, MD, DSc, discusses a recent publication detailing the termination of England's long-term national cancer plan.
Medscape Oncology, March 02, 2023
ESMO 2022 New Guidelines Provide 'Clear Blueprint' for Managing IO Toxicity David J. Kerr, CBE, MD, DSc, discusses the use of guidelines around the world.
Medscape Oncology, February 27, 2023
Ukrainian Refugees With Cancer: Where Does the Burden Go? Professor David Kerr discusses the challenge of cancer care for Ukrainian refugees and how Eastern Europe health systems are coping with it.
Medscape Oncology, February 23, 2023
Doctors in Film: Which Movies Are Most Inspirational to You? David Kerr, MD, discusses doctors in film and how films may inspire you or make you feel.
Medscape Oncology, January 13, 2023
Pharmacokinetically Guided Dosing: The Way Forward? Professor David Kerr discusses findings from a recent paper investigating pharmacokinetic principles to improve the delivery of oral targeted drugs.
Medscape Oncology, December 15, 2022
Cancer Control in Sub-Saharan Africa: Investment Needed Professor David Kerr provides an overview of a Lancet Oncology commission on cancer in sub-Saharan Africa and discusses the investment needed to improve cancer control.
Medscape Oncology, December 08, 2022
Using ctDNA to Guide Adjuvant Therapy in Stage II CRC Prof David Kerr discusses a paper illustrating the role of ctDNA as guiding adjuvant therapy decisions in stage II colorectal cancer.
Medscape Oncology, December 08, 2022
Devolved Healthcare: The Benefits and Drawbacks Prof David Kerr discusses the UK National Health Service and the benefits of a devolved government.
Medscape Oncology, December 07, 2022
Treatments From China: What Data Are Needed and Who Decides? Dr David Kerr discusses the need for improved regulatory consistency for medicines developed in individual ethnic populations.
Medscape Oncology, October 12, 2022
Why Can't UK Immunocompromised Patients Get Evusheld? Professor David Kerr discusses the controversy in the United Kingdom surrounding access to Evusheld.
Medscape Oncology, September 29, 2022
'The Queen and I': Reflections on Meeting Queen Elizabeth II Prof David Kerr discusses his encounters with Her Majesty Queen Elizabeth II and the journeys people have experienced during her reign.
Medscape Oncology, September 15, 2022
Could Lower-Dose ImmunoTx Provide More Equitable Global Access? Are Western doses of immunotherapy drugs too high? Join Dr David Kerr for this thought-provoking commentary on how reducing doses of oncology-related medications may help patients around the world attain better care.
Medscape Oncology, July 27, 2022
A Call to Action: Narrowing the Evidence-Practice Gap Professor David Kerr discusses an article highlighting the need for implementation research, particularly in oncology, to help close the gap between evidence and practice.
Medscape Oncology, July 07, 2022
The Case for 'Safe' Step Therapy David Kerr discusses step therapy, focusing on the potential to provide more access to innovative cancer medicines globally.
Medscape Oncology, May 02, 2022
A 'Wake-Up' Call to Resolve UK Cancer Drug Access David Kerr questions the policy that patients in Scotland with prostate cancer have access to olaparib, yet patients in the rest of the United Kingdom do not.
Medscape Oncology, April 26, 2022
Let's Do More to Support Ukrainian Refugees with Cancer Oncologist David Kerr pays tribute to colleagues who are helping Ukrainian patients with cancer flee the war.
Medscape Oncology, March 23, 2022
Focusing Cancer Resources After the Pandemic: Best Practices Professor David Kerr discusses a recent article providing a clear base on which to start to rebuild health economies of low- and middle-income countries after the COVID-19 pandemic.
Medscape Oncology, March 11, 2022
We're Finally Beginning to Crack the KRAS Nut in Colorectal Cancer After 30 years, we may at last have drugs to treat KRAS G12C-mutant colorectal cancer.
Medscape Oncology, March 08, 2022

No Results